Jin-Xiong She: Homocysteine beyond Heart Disease – The Methylation-Mobility Connection
Jin-Xiong She, Founder and CEO at Jinfiniti Precision Medicine, shared a post on LinkedIn:
“Longevity is not merely living longer.
It’s preserving the capacity to move, recover, and stay independent.
Homocysteine gets discussed almost exclusively as a heart disease marker.
That’s only part of what it reflects.
A 2025 study followed 170 older adults, grouped as robust, pre-frail, or frail.
Researchers measured B vitamins, homocysteine, and something less commonly tested: global DNA methylation, a marker of how well the body maintains its own genetic instructions over time.
- Chair stand ability, gait speed, and grip strength differed significantly across the three groups
- Folate and B6 levels varied depending on specific genetic variants tied to methylation
- Homocysteine sits directly in the same metabolic pathway as both
This is association-based research, not proof that lowering homocysteine prevents frailty.
But the biology behind it makes sense.
Homocysteine is cleared through a pathway that depends on B12 and folate acting as methyl donors, the same donors your body needs for DNA methylation more broadly.
When that pathway runs poorly, homocysteine tends to rise, methylation tends to falter, and physical performance may be part of what shows up downstream.
Most people only think to check homocysteine after a cardiovascular concern.
Grip strength and gait speed rarely prompt anyone to check it at all.
Kidney function matters too, since impaired clearance can elevate homocysteine independent of B vitamin status.
The mobility we associate with aging well may be tracking a metabolic pathway more directly than most people realize.”
Stay updated with Hemostasis Today.
-
Oct 16, 2026, 13:59Aya Akmal Amin: Antiphospholipid Syndrome Management and Risk Stratification
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy
-
Oct 16, 2026, 12:40Marc Carrier: Looking Ahead to ISTH 2027 in Vancouver
-
Oct 16, 2026, 12:30Bob Lempke: How One Blood Donation Can Save Up to Three Lives
-
Oct 16, 2026, 12:30Why VWF Therapies Belong on the EU Critical Medicines List – EHC